Title : Managing breast cancers with low estrogen receptor and HER2 by drugging both.

Pub. Date : 2014 Feb 1

PMID : 24352641






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer. Lapatinib estrogen receptor 1 Homo sapiens